cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Eqrx Inc
1 own
3 watching
Current Price
$2.21
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
856.83M
52-Week High
52-Week High
5.70500
52-Week Low
52-Week Low
1.58000
Average Volume
Average Volume
3.51M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization856.83M
icon52-Week High5.70500
icon52-Week Low1.58000
iconAverage Volume3.51M
iconDividend Yield--
iconP/E Ratio--
What does the Eqrx Inc do?
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company s pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Eqrx Inc make?
News & Events about Eqrx Inc.
Globe Newswire
5 months ago
SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firmRobbins LLPis investigating EQRx, Inc. (NASDAQ: EQRX) to determine whether certain EQRx officers and directors violated securities laws and breached fiduciary duties to shareholders. If you would like more information about our...
Globe Newswire
8 months ago
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced ...
Globe Newswire
9 months ago
Application is based on data from the pivotal Phase 3 GEMSTONE-302 trial assessing sugemalimab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancerAcceptance of the marketing authorization application (MAA) is EQRxs second from the United Kingdoms ...
Globe Newswire
9 months ago
Submission is EQRxs first to European Medicines AgencyApplication is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: ...
Globe Newswire
10 months ago
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced that management will participate in a fireside chat at the ...
Frequently Asked Questions
Frequently Asked Questions
What is Eqrx Inc share price today?
plus_minus_icon
Can Indians buy Eqrx Inc shares?
plus_minus_icon
How can I buy Eqrx Inc shares from India?
plus_minus_icon
Can Fractional shares of Eqrx Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Eqrx Inc stocks?
plus_minus_icon
What is today’s traded volume of Eqrx Inc?
plus_minus_icon
What is today’s market capitalisation of Eqrx Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Eqrx Inc?
plus_minus_icon
What percentage is Eqrx Inc down from its 52-Week High?
plus_minus_icon
What percentage is Eqrx Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.21
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00